UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcoma (40)

Participants in this study have been diagnosed with sarcoma that has spread. The purpose of the study is to test the combination of the chemotherapy drugs, gemcitabime, bevacizumab, valproic acid and docetaxel on the cancer. Approximately 45 people will take part in this study at the University of Iowa. Study involvement may last up to 3 years, which may include up to 50 visits. Follow up visits will take place every 3 months until disease progression.

Start Date
August 24, 2010
End Date
August 24, 2020
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Melanie Frees, 319-356-1228

bevacizumab ; cancer ; docetaxel ; gemcitabime ; IRB#200911736 ; milhem ; phase I/II ; phase one and two ; sarcoma ; valproic acid ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.